Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Histology-specific microRNA alterations in melanoma.

Poliseno L, Haimovic A, Segura MF, Hanniford D, Christos PJ, Darvishian F, Wang J, Shapiro RL, Pavlick AC, Berman RS, Hernando E, Zavadil J, Osman I.

J Invest Dermatol. 2012 Jul;132(7):1860-8. doi: 10.1038/jid.2011.451. Epub 2012 May 3.

2.

Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.

Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, Wang G, Vega Y Saenz de Miera EC, Medicherla R, Christos PJ, Shapiro R, Pavlick A, Darvishian F, Zavadil J, Polsky D, Hernando E, Ostrer H, Osman I.

Cancer Res. 2011 Apr 1;71(7):2561-71. doi: 10.1158/0008-5472.CAN-10-2958. Epub 2011 Feb 22.

3.

MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma.

Satzger I, Mattern A, Kuettler U, Weinspach D, Voelker B, Kapp A, Gutzmer R.

Int J Cancer. 2010 Jun 1;126(11):2553-62. doi: 10.1002/ijc.24960.

4.

MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC.

JAMA. 2008 Jan 30;299(4):425-36. doi: 10.1001/jama.299.4.425.

5.

Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.

Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn SA, Altmeyer P, Bechara FG.

Cell Tissue Res. 2013 Jan;351(1):85-98. doi: 10.1007/s00441-012-1514-5. Epub 2012 Oct 31.

PMID:
23111773
6.

Microrna profiling analysis of differences between the melanoma of young adults and older adults.

Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, Panelli MC.

J Transl Med. 2010 Mar 19;8:27. doi: 10.1186/1479-5876-8-27.

7.
8.

MicroRNA signatures differentiate melanoma subtypes.

Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB.

Cell Cycle. 2011 Jun 1;10(11):1845-52. Epub 2011 Jun 1.

10.

In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA.

Hanna JA, Hahn L, Agarwal S, Rimm DL.

Lab Invest. 2012 Oct;92(10):1390-7. doi: 10.1038/labinvest.2012.119. Epub 2012 Aug 13.

11.

Loss of microRNA-205 expression is associated with melanoma progression.

Liu S, Tetzlaff MT, Liu A, Liegl-Atzwanger B, Guo J, Xu X.

Lab Invest. 2012 Jul;92(7):1084-96. doi: 10.1038/labinvest.2012.62. Epub 2012 Apr 23.

12.

An assessment of clinical pathways and missed opportunities for the diagnosis of nodular melanoma versus superficial spreading melanoma.

Cicchiello M, Lin MJ, Pan Y, McLean C, Kelly JW.

Australas J Dermatol. 2016 May;57(2):97-101. doi: 10.1111/ajd.12416. Epub 2015 Nov 12.

PMID:
26563931
13.

IL-10Rα expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanoma.

Venza I, Visalli M, Beninati C, Benfatto S, Teti D, Venza M.

BMC Med Genomics. 2015 Dec 3;8:81. doi: 10.1186/s12920-015-0156-3.

14.

Diagnostic accuracy of malignant melanoma according to subtype.

Lin MJ, Mar V, McLean C, Wolfe R, Kelly JW.

Australas J Dermatol. 2014 Feb;55(1):35-42. doi: 10.1111/ajd.12121. Epub 2013 Nov 28.

PMID:
24283461
15.

Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians.

Carrera C, Gual A, Díaz A, Puig-Butillé JA, Noguès S, Vilalta A, Conill C, Rull R, Vilana R, Arguis P, Vidal-Sicart S, Alós L, Palou J, Castel T, Malvehy J, Puig S.

Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000340. [Epub ahead of print]

PMID:
28296711
16.

Identification of metastasis-suppressive microRNAs in primary melanoma.

Hanniford D, Segura MF, Zhong J, Philips E, Jirau-Serrano X, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Brown B, Osman I, Hernando E.

J Natl Cancer Inst. 2015 Feb 12;107(3). pii: dju494. doi: 10.1093/jnci/dju494. Print 2015 Mar.

17.

A novel miR-451a isomiR, associated with amelanotypic phenotype, acts as a tumor suppressor in melanoma by retarding cell migration and invasion.

Babapoor S, Fleming E, Wu R, Dadras SS.

PLoS One. 2014 Sep 19;9(9):e107502. doi: 10.1371/journal.pone.0107502. eCollection 2014.

18.

The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c.

Holst LM, Kaczkowski B, Glud M, Futoma-Kazmierczak E, Hansen LF, Gniadecki R.

Exp Dermatol. 2011 Mar;20(3):278-80. doi: 10.1111/j.1600-0625.2010.01163.x. Epub 2010 Dec 17.

PMID:
21166724
19.

Signatures of microRNAs and selected microRNA target genes in human melanoma.

Philippidou D, Schmitt M, Moser D, Margue C, Nazarov PV, Muller A, Vallar L, Nashan D, Behrmann I, Kreis S.

Cancer Res. 2010 May 15;70(10):4163-73. doi: 10.1158/0008-5472.CAN-09-4512. Epub 2010 May 4.

20.

Melanoma MicroRNA signature predicts post-recurrence survival.

Segura MF, Belitskaya-Lévy I, Rose AE, Zakrzewski J, Gaziel A, Hanniford D, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Osman I, Hernando E.

Clin Cancer Res. 2010 Mar 1;16(5):1577-86. doi: 10.1158/1078-0432.CCR-09-2721. Epub 2010 Feb 23.

Supplemental Content

Support Center